RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
EyeGate Pharmaceuticals Stock

EyeGate Pharmaceuticals Debt 2024

EyeGate Pharmaceuticals Debt

0 USD

Ticker

EYEG

ISIN

US30233M5031

WKN

A2PRBT

In 2024, EyeGate Pharmaceuticals's total debt was 0 USD, a 0% change from the 0 USD total debt recorded in the previous year.

EyeGate Pharmaceuticals Aktienanalyse

What does EyeGate Pharmaceuticals do?

EyeGate Pharmaceuticals Inc. is a US pharmaceutical company specializing in the development of ophthalmology products. It was founded in 1998 and is headquartered in Waltham, Massachusetts. The company aims to meet the need for safe and effective therapies for the treatment of eye diseases. Its business model focuses on the development and commercialization of products that enable faster and more effective treatment of eye diseases. The company has two main divisions. The first division includes iontophoretic drug delivery technologies used for the treatment of eye diseases. Iontophoresis is a process in which electric currents are used to transport medications through the skin and into the eyes. EyeGate Pharmaceuticals has developed the EyeGate® II Delivery System technology, which allows for non-invasive, painless, and safe administration of medications into the eye. The EyeGate II Delivery System can be used for the treatment of inflammation, pain, and infections in the eye area. The second division is the development of drugs used for the treatment of eye diseases. EyeGate Pharmaceuticals has several clinical programs in development, including EGP-437, a steroid-free corticosteroid used for the treatment of inflammation of the anterior eye segment. EGP-437 is currently being tested in two clinical trials to demonstrate its efficacy and safety in the treatment of pain and inflammation in the eye. In addition, the company has developed the drug EGP-259 for the treatment of dry eye. EyeGate Pharmaceuticals has previously entered into several partnerships with other companies to further develop and commercialize its technology platform. In 2019, the company entered into a partnership with Valeant Pharmaceuticals International, Inc. to advance the marketing of EGP-437 in the United States. EyeGate Pharmaceuticals aims to continue growing and expanding its presence in the field of ophthalmology in the coming years. The company is working on the development of new products and technologies that enable it to respond to the changing needs and challenges in ophthalmology. Overall, EyeGate Pharmaceuticals is committed to developing and marketing innovative and effective technologies and drugs for the treatment of eye diseases. The company is well positioned to grow in a rapidly evolving market and make a significant contribution to improving the health and quality of life of millions of people worldwide. EyeGate Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding EyeGate Pharmaceuticals's Debt Structure

EyeGate Pharmaceuticals's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing EyeGate Pharmaceuticals's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to EyeGate Pharmaceuticals’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in EyeGate Pharmaceuticals’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about EyeGate Pharmaceuticals stock

What is the debt of EyeGate Pharmaceuticals this year?

EyeGate Pharmaceuticals has a debt level of 0 USD this year.

What was the debt of EyeGate Pharmaceuticals compared to the previous year?

The debt of EyeGate Pharmaceuticals has increased by 0% compared to the previous year dropped.

What are the consequences of high debt for investors in EyeGate Pharmaceuticals?

High debt can pose a risk for investors of EyeGate Pharmaceuticals, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of EyeGate Pharmaceuticals?

Low debt means that EyeGate Pharmaceuticals has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from EyeGate Pharmaceuticals affect the company?

An increase in debt of EyeGate Pharmaceuticals can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of EyeGate Pharmaceuticals affect the company?

A reduction in debt of EyeGate Pharmaceuticals can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of EyeGate Pharmaceuticals?

Some factors that can influence the debt of EyeGate Pharmaceuticals include investments, acquisitions, operating costs, and revenue development.

Why are the debts of EyeGate Pharmaceuticals so important for investors?

The debts of EyeGate Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can EyeGate Pharmaceuticals take to change the debt?

To change the debt, EyeGate Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does EyeGate Pharmaceuticals pay?

Over the past 12 months, EyeGate Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, EyeGate Pharmaceuticals is expected to pay a dividend of 0.09 USD.

What is the dividend yield of EyeGate Pharmaceuticals?

The current dividend yield of EyeGate Pharmaceuticals is .

When does EyeGate Pharmaceuticals pay dividends?

EyeGate Pharmaceuticals pays a quarterly dividend. This is distributed in the months of July, August, September, October.

How secure is the dividend of EyeGate Pharmaceuticals?

EyeGate Pharmaceuticals paid dividends every year for the past 2 years.

What is the dividend of EyeGate Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0.09 USD are expected. This corresponds to a dividend yield of 0.25 %.

In which sector is EyeGate Pharmaceuticals located?

EyeGate Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von EyeGate Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of EyeGate Pharmaceuticals from 9/6/2024 amounting to 0.149 USD, you needed to have the stock in your portfolio before the ex-date on 9/3/2024.

When did EyeGate Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/6/2024.

What was the dividend of EyeGate Pharmaceuticals in the year 2023?

In the year 2023, EyeGate Pharmaceuticals distributed 0 USD as dividends.

In which currency does EyeGate Pharmaceuticals pay out the dividend?

The dividends of EyeGate Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von EyeGate Pharmaceuticals

Our stock analysis for EyeGate Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of EyeGate Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.